Efficacy and Safety of First-Line Chemoimmunotherapy with Durvalumab or Atezolizumab in Extensive-Stage of Small-Cell Lung Cancer in Real World Practice
The type of immune checkpoint inhibitor used in combination with chemotherapy did not significantly influence treatment outcomes, however, the presence of liver metastases emerged as a major adverse prognostic factor associated with shorter OS and PFS in patients with ES-SCLC treated with chemoimmunotherapy.
Abstract
: Background: Small-cell lung cancer (SCLC) is characterised by an aggressive clinical course and the early development of distant metastases. The introduction of immune checkpoint inhibitors to platinum-based chemotherapy has significantly improved survival outcomes. The aim of this study was to compare the efficacy and safety of two immunochemotherapy regimens with durvalumab and atezolizumab in patients with extensive-stage small-cell lung cancer (ES-SCLC) and different clinical characteristics. Methods: This retrospective study included 201 patients diagnosed with ES-SCLC, who received first-line treatment with either durvalumab (n = 104) or atezolizumab (n = 97) in combination with chemotherapy. Overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) were compared according to treatment regimen and clinical characteristics. The effectiveness of treatment was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). Treatment-related adverse events (TRAEs) were evaluated using the Common Terminology Criteria for Adverse Events (CTCAE version 5.0). Results: Disease control rates were comparable between the durvalumab and atezolizumab groups, with similar ORR observed in both cohorts. The median PFS was 6.3 months in the durvalumab arm and 6.0 months in the atezolizumab arm (HR = 0.8053, 95% CI: 0.5851–1.1083, p = 0.1839). Median OS was 16.9 months among patients treated with durvalumab and 12.0 months among those treated with atezolizumab (HR = 0.703, 95% CI: 0.4829–1.0233, p = 0.0658). In the overall study population, the presence of liver metastases was associated with a significantly higher risk of disease progression (HR = 1.5643, 95% CI: 1.1102–2.2244, p = 0.0127) and death (HR = 2.0848, 95% CI: 1.3886–3.1292, p = 0.0004). Conclusions: The type of immune checkpoint inhibitor used in combination with chemotherapy did not significantly influence treatment outcomes. However, the presence of liver metastases emerged as a major adverse prognostic factor associated with shorter OS and PFS in patients with ES-SCLC treated with chemoimmunotherapy.
Aim: The addition of atezolizumab to platinum-etoposide chemotherapy has become the standard first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, real-world data regarding treatment outcomes and prognostic factors remain limited. This study evaluated the effectiveness of first-line carbop...
A. Koçanoğlu, O. Ünsal, Ibrahim Karadag et al.· Ege Tıp Dergisi· 0 citations
The clinical benefit of adding atezolizumab appears attenuated in ES-SCLC patients age 75 years or older, supporting careful selection and age-adapted treatment strategies.
Yun-Gyoo Lee, Tae-Hwan Kim, Du-Young Kang et al.· Cancer research and treatmen...· 0 citations
Simple Summary This retrospective study evaluated the effectiveness and safety of adding a programmed death-ligand 1 (PD-L1) inhibitor to platinum-based chemotherapy in patients aged ≥75 year with extensive-stage small cell lung cancer. The combination treatment significantly prolonged overall survival compared with ch...
Minoru Kobayashi, Satoshi Watanabe, S. Hirose et al.· Cancers· 0 citations
Abstract Background Pembrolizumab monotherapy is standard of care in first line treatment of patients with stage IV lung cancer and programmed death ligand 1 (PD-L1) expression ≥ 50%. Whether the higher levels of PD-L1 expression predict higher benefit from the treatment with pembrolizumab is still debatable. Patients...
V. Stojšić, B. Zarić, P. Simurdić et al.· Radiology and Oncology· 0 citations
Atezolizumab was associated with lower medical costs and similar survival outcomes compared with durvalumab in ES-SCLC, suggesting its use as a clinically comparable option with lower associated costs in Japanese real-world practice.
K. Hirano, Akito Hata, Y. Yamanaka et al.· Japanese Journal of Clinical...· 0 citations
Real-world evidence is provided supporting the use of ICI-based therapy in SCLC, particularly in advanced-stage disease, but should be interpreted cautiously given the retrospective design and subgroup sample sizes.
Peng-Hu Gao, Hong-Bing Zhang, Ming-Hui Liu et al.· Frontiers in Oncology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.